MedPath

EBANGA

These highlights do not include all the information needed to use EBANGA™ safely and effectively. See full prescribing information for EBANGA. EBANGA (ansuvimab-zykl) for injection, for intravenous use Initial U.S. Approval: 2020

Approved
Approval ID

9c008384-379d-48d3-b5a5-9809ed0f655c

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

May 23, 2022

Manufacturers
FDA

Ridgeback Biotherapeutics, LP

DUNS: 116921498

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

ANSUVIMAB

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code80673-777
Application NumberBLA761172
Product Classification
M
Marketing Category
C73585
G
Generic Name
ANSUVIMAB
Product Specifications
Effective DateMay 23, 2022
FDA Product Classification

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

EBANGA - FDA Drug Approval Details